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1 GENERAL PART 
1.1 INTRODUCTION 
1.1.1 3,4-Methylenedioxymethamphetamine 
3,4-Methylenedioxymethamphetamine (MDMA), commonly named as Ecstasy, is a 
ring-substituted amphetamine with structural similarities to methamphetamine and 
mescaline. As other amphetamines, MDMA is a chiral compound carrying an 
asymmetric carbon atom in the side chain. It was first synthesized in Germany by 
Merck in 19141,2 and, although patented as an appetite suppressant, never marketed 
as a therapeutic drug.3 Since 1985, MDMA is scheduled in the Controlled Drugs and 
Substances Act as a restricted drug in the United States and since 1986, in 
Germany. It has become popular in the beginning of the 1990s as a drug of abuse 
among young people, especially in the dance scene.4,5 After decreasing numbers of 
MDMA users in recent years, most likely due to its non-availability on the illicit drug 
market, the Substance Abuse and Mental Health Services Administration has 
reported on increasing MDMA consumption in the United States again since 2010.6 
Usually it is consumed recreationally on weekends (1 to 2 pills of 75 to 120 mg every 
1 to 4 weeks) in form of tablets or pills.7 Preparations available on the illicit drug 
market usually contain the 1:1 racemate of R- and S-enantiomers. 
 
1.1.2 Pharmacology and Toxicology 
Similar to amphetamine or methamphetamine, MDMA acts in the central nervous 
system (CNS) as a stimulant through indirect release of monoamine 
neurotransmitters from presynaptic nerve terminals into the synaptic cleft where 
postsynaptic receptors can be stimulated.3,7 Mainly serotonergic (5-HT), 
noradrenergic (NA), and with a smaller effect dopaminergic (DA) neurotransmission 
is enhanced.  
The distinctive effects are described as an altered state of consciousness, euphoria, 
energy and a desire to socialize.3,8 However, MDMA also can induce severe acute 
- 1 -
 toxic symptoms, such as tachycardia, hypertension, hyperthermia, and 
hepatotoxicity. Severe and even fatal intoxications were described.3  
Concerning chronic toxicity, preclinical animal data suggest that MDMA causes 
irreversible damage to serotonergic nerve terminals in the CNS.3,9-11 In humans, 
chronic MDMA toxicity is still controversially discussed, as some recent publications 
suggest that animal doses may be too high compared to human 
pharmacokinetics.12,13 Other studies with recreational MDMA users, found decreased 
levels of 5-hydroxyindoleacetic acid, the main metabolite of 5-HT in the cerebrospinal 
fluid14 and a reduced density of serotonin transporters in the brain as determined by 
positron emission computed tomography with a ligand selective for these 
transporters.15 Unfortunately, these studies were performed with recreational users, 
so it cannot be excluded that the indicated neurotoxicity might also be due to use of 
other recreational drugs especially since polydrug use is not uncommon. Admittedly, 
direct MDMA injection into rat brain failed to reproduce neurotoxic effects seen after 
systemic administration.16 Furthermore, alteration of cytochrome P450 (CYP)-
mediated MDMA metabolism influenced MDMA-induced neurotoxicity.16,17 Therefore, 
MDMA metabolism may be an important contributor to neurotoxicity.18-21 Metabolites 
such as 3,4-dihydroxymethamphetamine (DHMA) can easily be oxidized to their 
corresponding quinones which can form adducts with glutathione and other thiol-
containing compounds.18-20 Recently, such adducts have been implicated in MDMA 
neurotoxicity.22,23 
For the two enantiomers, different pharmacological properties were observed.3 While 
S-MDMA is generally more potent and responsible for the described psychostimulant 
and empathic effects, the R-isomer exhibits more hallucinogenic-type properties.10 R- 
and S-MDMA also differ in their dose-response curves for changes in serotonergic 
function and neurotoxicity and their in vivo kinetics are known to be different.3,8,24-27 
 
1.1.3 Metabolism 
In vivo and in vitro MDMA studies revealed two main metabolic pathways as shown 
in Figure 1. The predominant pathway in humans involves multiple CYP enzyme-
catalyzed O-demethylenation of MDMA to DHMA, followed by catechol-O-
methyltransferase (COMT)-catalyzed O-methylation, primarily to 4-hydroxy-3-
methoxymethamphetamine (HMMA). DHMA and HMMA also may be conjugated by 
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 uridine diphosphate glucuronyltransferases (UGT) to DHMA 3-glucuronide, DHMA 4-
glucuronide, and HMMA glucuronide, or by sulfotransferases (SULT) to DHMA 3-
sulfate, DHMA 4-sulfate, and HMMA sulfate. A minor pathway includes 
demethylation to 3,4-methylendioxyamphetamine (MDA) followed by 
demethylenation to 3,4-dihydroxyamphetamine (DHA), O-methylation to 4-hydroxy-3-
methoxyamphetamine (HMA), and respective conjugation.10,28-30 The catechols 
DHMA and DHA, formed via metabolic demethylenation of MDMA, are suspected to 
be oxidized to their corresponding ortho-quinones which in turn can form adducts 
with glutathione and other thiol-containing compounds.19,31  
 
 
 
Fig. 1 Metabolic pathways of MDMA in humans 
 
Different pharmacokinetic properties have been observed for the two MDMA 
enantiomers. The S-enantiomer is eliminated from plasma at a higher rate than the 
R-enantiomer3,8,24-27 most likely explained by stereoselective metabolism. In vitro 
experiments concerning CYP-N-demethylation, CYP-O-demethylenation, and COMT-
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 methylation of DHMA to HMMA indeed revealed metabolic preferences for the S-
enantiomers.32,33 
 
1.1.4 Phase II Metabolizing Enzymes 
Numerous enzymes are capable to metabolize xenobiotics, usually resulting in 
decreased toxicity and increased hydrophilicity compared to the parent compounds, 
which promotes their excretion. Generally, these biotransformations can be divided in 
two steps: phase I and phase II metabolism. Phase I metabolism is referred to as 
functionalization which mainly involves oxidation, reduction, or hydrolysis. Phase II 
type reactions are conjugative reactions, catalyzing among others, the transfer of 
hydrophilic residues such as glucuronic acid or activated sulfate. However, 
conjugation is not necessarily a secondary phase reaction as many endogenous 
compounds or xenobiotics can be directly glucuronidated or sulfated.  
 
1.1.4.1 UDP-Glucuronyltransferase (UGT) 
UGTs represent a superfamily of endoplasmic reticulum membrane-bound enzymes, 
postulated to reside on the luminal surface. Based on primary amino acid identity, 
they are divided into two families, UGT1 and UGT2. At present, 15 different 
isoenzymes are known in humans: UGT1A1, UGT1A3, UGT1A4, UGT1A5, UGT1A6, 
UGT1A7, UGT1A8, UGT1A9, and UGT1A10 and UGT2B4, UGT2B7, UGT2B10, 
UGT2B11, UGT2B15, and UGT2B17,34-36 whereas UGT1A1, 1A3, 1A4, 1A6, 1A9, 
2B7, and 2B15 are considered to be of greatest importance in hepatic drug 
elimination.36 Although the liver is recognized as the major site of glucuronidation, 
numerous organs, e.g. small intestine, lung, kidney, brain, etc. significantly contribute 
to the overall glucuronidation capacity.  
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Fig. 2 Schematic of the glucuronidation reaction 
 
UGTs catalyze the transfer of glucuronic acid from the co-substrate uridine 5’-
diphosphoglucuronic acid (UDPGA) to a multitude of functional groups as shown 
schematically in Figure 2. The underlying mechanism is a SN2 reaction where the 
configuration of the glucuronic acid changes from α- to β-anomer. Virtually all classes 
of drugs are substrates for UGTs, hence about 35% of phase II drug metabolism are 
estimated to underlie this pathway.37 Although, glucuronidation generally results in 
the formation of water-soluble, inactive metabolites, it is known that also active and 
reactive glucuronides exist. For example, morphine 6-O-glucuronide shows greater 
pharmacologic activity than its parent compound morphine35 and glucuronides of 
carboxylic acids exhibit electrophilic reactivity associated with cytotoxic, carcinogenic, 
and idiosyncratic hypersensitivity reactions.35 
A number of polymorphisms have been described for different UGT isoenzymes and 
significant pharmacological impact have been demonstrated.37 However, the clinical 
outcome of many polymorphisms is still controversial and additional studies are 
needed to promote the understanding of interindividual variations in the 
glucuronidation pathway.  
 
1.1.4.2 Sulfotransferase (SULT) 
In the mammalian organism, SULTs occur membrane-bound or soluble in cytosol. 
Membrane SULTs, localized in the Golgi apparatus, are responsible for the sulfation 
of endogenous structures, such as carbohydrates and proteins. Only cytosolic SULTs 
play a role in xenobiotic metabolism, as well as in the biotransformation of thyroid 
hormones, steroids, and neurotransmitters. Considerable numbers of cytosolic 
SULTs have been characterized and divided into several gene families based on 
similarity of their amino acid sequences.38,39 Out of 13 human SULTs currently 
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 known, the major isoforms responsible for human xenobiotic metabolism are 
SULT1A1, SULT1A3, SULT1B1, SULT1E1, and SULT2A1.40 The widest tissue 
distribution was shown for the SULT1A subfamily, with SULT1A1 as the major 
isoform present in human liver, but also in the gastrointestinal tract, brain and 
placenta.39,40 SULT1A3 is known to be only scarcely expressed in human liver, 
however highly expressed in the small intestine, brain and fetal liver.39,40 
SULTs catalyze the transfer of a sulfonate group from 3’-phosphoadenosine-5’-
phosphosulfate (PAPS) to nucleophilic sites of their substrates. Sulfation is a high 
affinity and low capacity phase II reaction, with overlapping substrates spectra for 
glucuronidation. Sulfation predominates at low substrate concentrations and 
glucuronidation at high substrate concentrations, when sulfation is saturated.39 The 
limiting factor for sulfation is the availability of PAPS. Although it can be rapidly 
synthesized, it depends on the hepatic sulfate concentrations, which are largely 
dependent on equilibrium with circulating inorganic sulfate.39 
 
 
 
Fig. 3 Schematic of the sulfation reaction 
 
Generally, sulfation is a detoxification process, however, labile and chemically 
reactive intermediates are sometimes formed, which can undergo DNA binding, 
leading to mutagenicity and carcinogenicity. Some sulfate esters including minoxidil, 
triamterene and morphine were reported to be more pharmacologically active than 
the corresponding parent drugs.41 At least some endogenous sulfate conjugates 
seem to play a role in the CNS. For example, dopamine 4-sulfate demonstrated 
vasopressor activity in the peripheral and central nervous system, whereas dopamine 
3-sulfate acted as a central depressor.41 Several xenobiotics, among them dietary 
and environmental chemicals, therapeutic drugs, etc. were shown to inhibit one or 
more SULT isoenzymes and may cause adverse effects on human health.41 
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 1.1.5 Synthesis of Phase II Metabolites 
Reference standards of metabolites are needed for in vitro and in vivo kinetic studies. 
However, the number of commercially available glucuronide or sulfate standards is 
limited, hence it usually requires their synthesis prior to kinetic studies. 
 
1.1.5.1  Glucuronides 
Synthesis of glucuronides can be achieved either by chemical42,43 or enzymatic 
methods.44 Chemical synthesis requires multiple steps, most commonly via acyl-
protected intermediates. Hydrolytic stability of the aglycones is therefore a 
prerequisite necessary for the removal of protecting groups. α-Anomers and other 
byproducts in addition to the desired β-anomer can occur leading to more 
complicated purifications and low yields. In the case of aglycones that contain 
several possible glucuronidation sites, without further protecting groups mono- and 
polyglucuronides can be formed.42,43,45 Shima et al.46 previously synthesized HMMA 
O-glucuronide by chemical synthesis achieving yields of 6%, which seems rather low. 
Enzyme-assisted synthesis represents a suitable alternative to chemical synthesis, 
especially when milligram scale yields are sufficient. Isolated purified UGT enzymes 
or liver microsomes might be applied as convenient catalysts for glucuronidation. 
However, liver microsomes of different species (rat, mouse, dog, monkey, human) 
seems most appropriate due to easy preparation and handling. Use of enzymes does 
not require multiple steps and results in the formation of the natural configuration. 
Mainly mono-glucuronides and even regio- and stereoselective glucuronides are 
obtained.45 Yields with up to 100% depending on the aglycone and the microsomal 
source used could be reached.44,45 Therefore, an enzyme-assisted synthesis was 
chosen to produce milligram amounts of the diastereomeric HMMA glucuronides as 
described in detail under 2.1. 
 
1.1.5.2 Sulfates 
Synthesis of sulfate conjugates is usually performed with chemical methods. Only 
few data using enzymatic synthesis are available.47-49 Although enzymatic sulfate 
synthesis bears the advantages of regio- and stereoselective conjugation, there are 
some major drawbacks limiting its usefulness. The main issue is the need for the co-
substrate. PAPS is rather expensive and unstable. The formed product 3’-
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 phosphoadenosine 5’-phosphate (PAP) leads to product inhibition.49 Incubations with 
subcellular fractions and the addition of PAPS therefore provide only low sulfation 
capacities. Uutela et al used rat liver S9 fractions with the addition of PAPS for 
regioselective sulfation of 5-HT, 5-HIAA, DOPAC, and HVA. However, the yields 
were less than 3 mg (less than 10%) and hence too low for NMR confirmation of the 
sulfation side.47 Chemical synthesis seems to be the method of choice for sulfate 
synthesis of xenobiotics.47,48 Different strategies have been described, e.g. use of 
sulfuric acid47,48 or sulfur trioxide-amine complexes.46,48 As H2SO4 is not amenable to 
sulfation for many sensitive scaffolds considering the strong acidity of sulfuric acid, 
SO3 adducts with amine containing molecules link pyridine, trimethylamine, 
triethylamine, or DMF provide the most straightforward method.48 Usually, yields with 
up to 90% could be achieved. Sulfates of DHMA and HMMA were synthesized using 
a pyridine SO3 complex as described in detail under 2.2.  
 
1.1.6 (Enantioselective) In vitro Enzyme Kinetic Studies 
The characterization of humane enzymes involved in the metabolism of specific 
drugs and the determination of their enzyme kinetic parameters, such as KM and Vmax 
is an important aspect in toxicological risk assessment. They can be used as 
potential determinants of interindividual variability in pharmacokinetics, e.g. drug-drug 
interactions or genetic polymorphisms. KM and Vmax values represent descriptors of 
the enzyme kinetic behavior of a respective biotransformation reaction. Assuming 
simple kinetic systems, Vmax is the maximum enzyme velocity at an infinite substrate 
concentration and in general represents the capacity of an enzymatic reaction. The 
KM value is defined as the substrate concentration that will yield a reaction velocity 
that is half of Vmax and reflects the substrate affinity to a certain enzyme. The overall 
effectiveness of a respective reaction is usually described by the Vmax/KM ratio and 
should increase the higher this ratio is. This fact sounds reasonable, as the catalytic 
efficiency value is getting higher with increasing affinity (low KM) and increasing 
velocity (high Vmax). Concerning differences in metabolic clearance of R- or S-
stereoisomers, enantioselectivity can also be evaluated via the Vmax/KM values and 
marked enantioselectivity was previously defined as Vmax/KM(S-stereoisomer)/Vmax/KM(R-
stereomer) > 1.5 or < 0.67).32 
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 1.1.6.1 Product formation approach 
Conventional determinations of enzyme kinetic parameters are made by assessing 
the rate of product (metabolite) formation at several substrate concentrations. 
Therefore, methods are required for measurement of metabolite concentrations in in 
vitro matrices. Such analytical methods themselves require that metabolites have 
been definitely identified, suitable chromatographic separation has been established 
and authentic standards prepared.50 The simplest model to describe enzymatic 
biotransformation and hence to calculate KM and Vmax is fitting the initial rate velocities 
at various substrate concentrations to the Michaelis Menten equation (eq. 1).  
 
][
][max
SK
SVV
m +
×=
 
 
A prerequisite are “initial” rate conditions, meaning protein concentrations and 
incubation time should be within the linear range of metabolite formation, and in total 
less than 20% of substrate should be consumed.  
 
1.1.6.2 Substrate depletion approach 
An alternative to the measurement of product formation is the determination of 
substrate depletion, which was successfully used for CYP reactions in both, human 
liver microsomes (HLM) and recombinant enzymes.50,51 Substrate consumption over 
time can be used to calculate initial substrate depletion rates (kdep) at various 
substrate concentrations. In theory, when substrate concentrations are well below 
KM, the depletion should follow first-order decay kinetics.52 As the substrate 
concentration is elevated through the KM value, the measured values for kdep should 
decline and become more zero-order in character. The infliction point of this 
relationship represents the KM value and should occur at a substrate concentration 
that yields a kdep value that is half of the theoretical maximum kdep at an infinitesimally 
low-substrate concentration (kdep([S]=0)).50 Plotting of kdep values versus substrate 
concentrations allows calculation of KM according to equation 2.50 
 
)
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 The theoretical validity of this approach has been confirmed by Nath and Atkins,53 
who showed on a simulated data set that equation 2 can be derived from the 
Michaelis-Menten equation (eq. 1) and, as such, the kinetic parameters obtained 
should be comparable with those obtained by the traditional product-formation 
approach. The major advantage of the substrate-depletion approach is that reference 
standards of metabolites are not required. For some analytes, when 
(enantioselective) chromatographic separation of metabolites could not be 
accomplished sufficiently, (chiral) measurement of substrate consumption might be a 
versatile alternative to the conventional product formation. However, the substrate 
depletion approach possesses some practical limitations.50 Substrates exhibiting low-
intrinsic clearance will be difficult to examine, since measurement of substrate 
depletion requires a substantial consumption of the initial substrate concentration 
during the incubation period. Furthermore, enzyme kinetics of formation of individual 
metabolites cannot be determined, as the KM and Vmax values would only represent 
the sum of kinetic parameters for all single metabolic pathways.  
 
 
- 10 -
 1.2 AIMS AND SCOPES 
Phase II metabolism represents an important detoxification process.34,35,38 
Investigation of glucuronidation and sulfation as a secondary metabolic step is 
especially important concerning the detoxification of reactive phase I metabolites. 
Such metabolites are known to be formed in humans after ingestion of MDMA, 
mainly through demethylenation to the catecholic metabolite DHMA and are 
suspected to contribute to MDMA’s neurotoxic effects.18,19,19,20,54 The qualitative and 
quantitative phase I metabolism of MDMA was studied extensively in vitro and in 
vivo.10,28-30,32,33,55 Several pharmacokinetic studies in blood and urine following 
controlled MDMA administration to humans were performed, but DHMA, HMMA, 
and/or HMA urinary pharmacokinetic data were only obtained after conjugate 
cleavage. Only Shima et al. determined intact HMMA conjugates in 25 random urine 
samples and found that more than 70% of HMMA was eliminated as glucuronide or 
sulfate.30 However, neither systematic in vivo nor in vitro kinetic studies were 
available concerning glucuronidation and sulfation of MDMA’s phase I metabolites.  
Furthermore, different pharmacological and pharmacokinetic properties were 
observed for the two enantiomers of MDMA3,8,24-26 and enantiomeric preferences in 
the phase I metabolism were observed in vitro32,33 and in vivo.27 Elucidation whether 
the phase II metabolism also contributes to this phenomenon is important from the 
toxicological and pharmacological point of view. 
Besides this, MDMA is known to be a potent mechanism-based inhibitor of 
CYP2D656 which is also assumed to influence MDMA-induced neurotoxicity.16,17 
DHMA was also shown to inhibit its own metabolism as well as the methylation of 
dopamine.33 The inhibition potential of MDMA and/or its metabolites on other 
metabolic enzymes, such as UGTs or SULTs, is still unknown.  
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 Therefore, the aims of the presented studies were: 
 
- (Bio)Synthesis of MDMA’s main phase II metabolites as reference standards for 
quantitative in vitro and in vivo kinetic studies 
 
- Investigation of stereoselective enzyme kinetic data in vitro for HMMA 
glucuronidation in HLM and recombinant UGTs, and DHMA and HMMA sulfation 
in human liver cytosol (HLC) and recombinant SULT 
 
- Determination of the inhibition potential of MDMA, DHMA, and HMMA on SULT 
 
- Development and full validation of gas chromatography-mass spectrometry (GC- 
MS) and liquid chromatography-mass spectrometry (LC-MS) methods allowing 
the stereoselective analysis of MDMA, its phase I and phase II metabolites in 
human urine 
 
- Evaluation of MDMA’s phase II metabolites elimination kinetics in human urine 
following controlled oral MDMA administration 
 
- Determination of stereoselective elimination kinetics of MDMA and its phase I and 
II metabolites in human urine following controlled oral MDMA administration 
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2 PUBLICATIONS OF THE RESULTS 
The results of the studies were published in the following papers: 
 
2.1 THE ROLE OF HUMAN UGT-GLUCURONYLTRANSFERASES ON THE 
FORMATION OF THE METHYLENEDIOXYMETHAMPHETAMINE (ECSTASY) 
PHASE II METABOLITES R- AND S-3-METHOXYMETHAMPHETAMINE 4-O-
GLUCURONIDES57 (DOI: 10.1124/DMD.109.029215) 
- 13 -
  
 2.2 SULFATION OF THE 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) 
METABOLITES 3,4-DIHYDROXYMETHAMPHETAMINE (DHMA) AND 4-
HYDROXY-3-METHOXYMETHAMPHETAMINE (HMMA) AND THEIR 
CAPABILITY TO INHIBIT HUMAN SULFOTRANSFERASES58 
(DOI: 10.1016/JTOXLET.2011.01.026) 
- 15 -
  
 2.3 INVESTIGATION ON THE ENANTIOSELECTIVITY OF THE SULFATION OF THE 
METHYLENEDIOXYMETHAMPHETAMINE (MDMA) METABOLITES 3,4-
DIHYDROXYMETHAMPHETAMINE (DHMA) AND 4-HYDROXY-3-
METHOXYMETHAMPHETAMINE (HMMA) USING THE SUBSTRATE 
DEPLETION APPROACH59 (DOI: 10.1124/DMD.111.041129) 
- 17 -
  
 2.4 DEVELOPMENT AND VALIDATION OF LC-HRMS AND GC-NICI-MS 
METHODS FOR STEREOSELECTIVE DETERMINATION OF MDMA AND ITS 
PHASE I AND II METABOLITES IN HUMAN URINE60 
(DOI: 10.1002/JMS.1929) 
- 19 -
  
 2.5 HUMAN MDMA AND PHASE I AND PHASE II METABOLITE URINARY 
EXCRETION KINETICS FOLLOWING CONTROLLED MDMA 
ADMINISTRATION61 
(DOI: 10.1373/CLINCHEM.2011.172254) 
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3 CONCLUSIONS 
The studies presented here provided systematic data on the in vitro glucuronidation 
and sulfation kinetics of the designer drug 3,4-methylenedioxymethamphetamine, 
(MDMA, Ecstasy). These data suggested, that sulfation was the predominant 
conjugation step with regioselective sulfation of the catecholic metabolite DHMA in 
position 3.57,58 Inhibition studies performed with MDMA, DHMA, and HMMA towards 
typical sulfation reactions clearly indicated a mixed-type or competitive inhibition of 
dopamine sulfation by DHMA and HMMA, respectively, with IC50 values likely to 
cause significant inhibition in vivo after recreational MDMA doses.63 In the author’s 
opinion, a part of the described neurotoxicity of MDMA3,9-11 could be explained by 
inhibition of the dopamine sulfation in the CNS. As MDMA and related drugs are able 
to increase the concentration of dopamine and other neurotransmitters in the CNS64 
and as they additionally could inhibit the inactivation of these compounds,33 the 
described dopamine induced neurotoxicity might be enhanced.65  
Additionally, evaluation with respect to a possible enantioselective phase II 
metabolism was performed. It could be shown, that HMMA glucuronidation by 
UGT1A9 was markedly stereoselective with preferences for the formation of the S-
diastereomer whereas its glucuronidation by UGT2B7 favored the R-isomer. 
UGT2B15 and UBT2B17 revealed only slight preferences for S-HMMA. In human 
liver microsomes, which contain a physiological mixture of all liver UGT isoenzymes, 
and should therefore reflect the in vivo situation, slight preferences for S-HMMA were 
observed. Sulfation of HMMA was mainly catalyzed by SULT1A3 and to a minor 
extent by SULT1E1. Neither for SULT1A3 nor in human liver cytosol enantiomeric 
preferences could be observed. On the other hand, the efficiency for S-DHMA 3-
sulfate formation was twice as high as for its R-enantiomer, both in SULT1A3 and 
human liver cytosol. One reason for this difference in enantioselectivity might be the 
position for sulfation. DHMA was mainly sulfated in position 3, whereas HMMA could 
only be sulfated in position 4.  
To further obtain systematic in vivo data on MDMA’s phase II metabolism and its 
enantioselectivity, liquid chromatography-high resolution mass spectrometry (LC-
HRMS) and gas chromatography-negative ion chemical ionization- mass 
spectrometry (GC-NICI-MS) methods were successfully developed and validated.60 
These methods were shown to be applicable for the analysis of urine samples of 10 
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 human subjects collected for up to 7 days following controlled oral placebo, low, and 
high dose MDMA administration.61,62 Human MDMA urinary metabolites are primarily 
sulfate and glucuronide conjugates, with sulfates present in higher concentrations 
than glucuronides. HMMA sulfate was shown to be the major urinary metabolite 
providing the longest detection time for MDMA consumption with up to 168 h. All 
metabolites exhibited changes in enantiomeric disposition over time. MDMA, DHMA, 
and HMMA sulfate revealed preferences for the R-stereoisomers, all other 
metabolites showed conversely more S-isomer within the first 24 h after ingestion. 
Generally, initial stereoisomer preferences mimicked those observed in previous in 
vitro experiments.32,33,57,59 In the later excretion phase (after 24 h), R/S ratios were >1 
for all compounds. This is quite remarkable, as the enantiomeric ratios of at least one 
metabolite should be reversed from that of MDMA. However, it must be considered 
that urinary analysis reflects not only metabolite formation, but also distribution and 
elimination processes. Metabolism is represented mainly within the first 12 to 24 h, 
whereas later on, elimination is more relevant. One explanation for the observed 
time-dependency could be substrate availability. With increasing time, the amount of 
R- relative to S-enantiomers could increase, leading to increased metabolism of R-
enantiomers, although affinity for S-enantiomers is higher. However, this only applies 
for analytes with initial preferences for S-enantiomers. On the other hand, distribution 
processes, including transport protein availability, could play a major role in 
enantioselective disposition and metabolite excretion. Changes in the R/S ratios over 
time could be used for estimation of ingestion time and to distinguish between recent 
(within 24 h) or earlier ingestion MDMA consumption. R/S cut-offs ≥ 2 for MDMA, 
HMMA sulfate, and HMMA glucuronide, and ≥ 1 for MDA, HMMA, and DHMA sulfate 
correctly predicted time of ingestion in more than 87% of all samples. However, so 
far these calculations were only performed after administration of a single MDMA 
dose. Recreational users might ingest repeated MDMA doses which would require 
further studies to show the applicability of such an estimation model after multiple 
doses.  
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4 SUMMARY 
In the presented studies, the phase II metabolism of MDMA was investigated in vitro 
and in vivo. Furthermore, evaluation with respect to a possible stereoselective phase 
I and II metabolism was performed. The in vitro data indicated that sulfation is the 
major conjugation step with regioselective preferences for position 3 of DHMA. Both 
MDMA phase I metabolites, DHMA and HMMA, showed inhibition potential towards 
dopamine sulfation with IC50 values likely to be reached after recreational MDMA 
doses. Inhibition of dopamine degradation occurring in the central nervous system 
could be another reason for the drug-induced irreversible damage to central nerve 
terminals associated with MDMA consumption. Enantioselectivity was observed for 
DHMA sulfation and HMMA glucuronidation, but not for HMMA sulfation. In vivo 
urinary data obtained from 10 participants following controlled placebo, low and high 
dose MDMA administration supported the results from the in vitro experiments. 
HMMA sulfate was shown to be the major urinary metabolite providing the longest 
detection time for MDMA consumption. Enantiomeric ratios of all metabolites showed 
steady increases of R-isomers as a function of ingestion time allowing distinguishing 
between recent or earlier MDMA ingestion.  
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6 ABBREVIATIONS 
MDMA 3,4-methylenedioxymethamphetamine 
NA noradrenaline 
5-HT serotonin 
DA dopamine 
CNS central nervous system 
CYP Cytochrome P450 
DHMA 3,4-dihydroxymethamphetamine 
COMT catechol-O-methyltransferase 
HMMA 4-hydroxy-3-methoxymethamphetamine 
UGT uridine diphosphate glucuronyltransferase 
SULT sulfotransferase 
MDA 3,4-methylenedioxyamphetamine 
DHA 3,4-dihydroxyamphetamine 
HMA 4-hydroxy-3-methoxyamphetamine 
UDPGA uridine 5’-diphosphoglucuronic acid 
PAPS 3’-phosphoadenosine-5’-phosphosulfate 
PAP 3’-phosphoadenosine-5’-phosphate 
HLM human liver microsomes 
HLC human liver cytosol 
GC gas chromatography 
MS mass spectrometry 
LC liquid chromatography 
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7 ZUSAMMENFASSUNG 
Im Rahmen dieser Dissertation wurde der Phase II Metabolismus von MDMA in vitro 
und in vivo untersucht. Darüber hinaus wurden die Daten auf einen möglichen 
stereoselektiven Phase I und II Metabolismus hin ausgewertet. Die in vitro 
Experimente haben gezeigt, dass die Sulfatierung die Hauptkonjugationsreaktionen 
darstellt, wobei für DHMA eine Regioselektivität für die 3 Position beobachtet wurde. 
Es wurde ebenfalls gezeigt, dass DHMA und HMMA die Sulfatierung von Dopamin 
hemmen können, mit IC50- Werten wie sie nach üblichem Gebrauch von MDMA 
erwartet werden. Diese Inhibition könnte, wenn sie im Zentralnervensystem auftritt, 
eine weitere Ursache für die MDMA-induzierte irreversible Schädigung von Neuronen 
sein. Die Sulfatierung von DHMA und die Glucuronidierung von HMMA, nicht aber 
die HMMA Sulfatierung waren enantioselektiv. Die Ergebnisse der in vitro-
Experimente wurden bestätigt durch in vivo Daten von 10 Teilnehmern, die im 
Rahmen einer kontrollierten MDMA-Studie jeweils ein Placebo, eine Niedrig- oder 
eine Hochdosis erhalten haben. HMMA-Sulfat war in vivo der Hauptmetabolit, der die 
längste Nachweisbarkeit einer MDMA Einnahme ermöglicht. Die 
Enantiomerenverhältnisse aller untersuchter Verbindungen zeigten eine stetige 
Zunahme der R-Enantiomere über die Zeit, was es erlaubt zwischen einem rezenten 
und einem länger zurückliegenden MDMA Konsum zu unterscheiden.  
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